Agenus (AGEN) Misses Q1 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. DRS
4. GS
5. BAC
6. UNH
7. ORCL
8. AVAV
9. ACI
10. SPY

Go back to Agenus (AGEN) Misses Q1 EPS by 14c

Agenus Reports First Quarter 2016 Financial Results and Operational Progress

April 28, 2016 8:50 AM EDT

Company to host conference call at 11am ET today

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

In the first quarter we advanced our checkpoint antibodies by gaining FDA clearance for the Investigational New Drug applications for our CTLA-4 antagonist antibody AGEN1884, and for our GITR agonist antibody partnered with Incyte, INCAGN1876, said Garo H. Armen, Ph.D., Chairman and CEO of... More